Medical note: This article is for educational purposes only and is not a substitute for advice from a licensed healthcare professional. If you have COVID-19 symptoms, a positive test, worsening breathing, chest pain, confusion, dehydration, or other urgent symptoms, contact a healthcare provider or seek emergency care.
Veklury is the brand name for remdesivir, an antiviral prescription medicine used to treat COVID-19. It became widely known during the early pandemic years, but it has continued to matter because COVID-19 has not exactly packed its suitcase and left town. While most people now think first of at-home antivirals, Veklury remains an important option for certain hospitalized patients and for some high-risk nonhospitalized patients who need treatment early.
Unlike pills that sit in a medicine cabinet, Veklury is given by intravenous infusion. In plain English: it goes into a vein under medical supervision. That makes it less convenient than swallowing tablets, but it also means healthcare professionals can monitor patients, check labs, and respond quickly if a reaction occurs. Think of it as the “serious equipment” option in the COVID-19 treatment toolboxnot casual, not DIY, and definitely not something to order like takeout.
What Is Veklury?
Veklury is an antiviral medicine that contains the active ingredient remdesivir. It belongs to a class of medicines known as nucleotide analogs. Its job is to interfere with the way SARS-CoV-2, the virus that causes COVID-19, copies itself inside the body.
Viruses are tiny copy machines with attitude. Once SARS-CoV-2 enters human cells, it tries to replicate. Remdesivir is designed to disrupt that replication process by interfering with the viral RNA polymerase enzyme. When the virus cannot copy itself efficiently, the infection may be easier for the body and medical treatment plan to control.
Veklury is not a vaccine, not a pain reliever, and not a general immune booster. It does not prevent infection before exposure, and it is not used for every person who tests positive. It is a prescription COVID-19 treatment selected by clinicians based on timing, risk level, disease severity, oxygen needs, age, weight, medical history, and practical access to an infusion site.
Who Makes Veklury?
Veklury is made by Gilead Sciences, Inc., a U.S.-based biopharmaceutical company headquartered in Foster City, California. Gilead is known for antiviral medicines, especially in areas such as HIV, hepatitis, and emerging viral infections.
Remdesivir was originally investigated before COVID-19 for other viral diseases. During the COVID-19 pandemic, it became one of the first antiviral treatments studied in large clinical trials for hospitalized patients. The FDA later approved Veklury for specific COVID-19 treatment uses. Today, the brand name Veklury and the generic name remdesivir are often used together because patients may hear one term from a doctor and the other from a pharmacy, hospital bill, or news report.
What Is Veklury Used For?
Veklury is used to treat COVID-19 in adults and pediatric patients who meet FDA-approved criteria. It may be used in patients who are hospitalized with COVID-19, and it may also be used in nonhospitalized patients who have mild-to-moderate COVID-19 and are at high risk for progression to severe disease, including hospitalization or death.
Use in Hospitalized Patients
In hospitals, Veklury may be used for patients with COVID-19 who need medical care, including some patients who require oxygen support. The treatment course is commonly 5 days for hospitalized patients who do not require invasive mechanical ventilation or extracorporeal membrane oxygenation, sometimes extended up to 10 days depending on clinical response. For patients who require invasive mechanical ventilation or ECMO, a 10-day course may be used.
The goal in hospitalized patients is not simply to “kill COVID instantly.” Medicine rarely works like a superhero movie. The goal is to reduce viral replication early enough to improve the clinical course, support recovery, and fit into the broader treatment plan, which may include oxygen, steroids, immune-modulating drugs, fluids, blood clot prevention, or other supportive care.
Use in High-Risk Nonhospitalized Patients
For nonhospitalized patients, Veklury may be used when someone has mild-to-moderate COVID-19 but is at higher risk of developing severe illness. This may include older adults and people with certain chronic conditions such as diabetes, obesity, immune suppression, chronic kidney disease, chronic lung disease, cardiovascular disease, or other risk factors identified by a clinician.
Timing matters. For outpatient use, Veklury is generally started as soon as possible after COVID-19 diagnosis and within 7 days of symptom onset. The outpatient treatment course is typically one IV infusion daily for 3 consecutive days. That schedule can be inconvenient, but for some patients it may be a valuable option, especially when other antiviral treatments are not appropriate because of drug interactions, kidney or liver considerations, or availability.
How Is Veklury Given?
Veklury is given only by IV infusion. It is not a tablet, capsule, syrup, nasal spray, or home remedy. Healthcare professionals prepare the medication, dilute it properly, and administer it in a medical setting where allergic or infusion-related reactions can be treated if they occur.
For adults and pediatric patients weighing at least 40 kg, the usual dosing pattern begins with a 200 mg loading dose on Day 1, followed by 100 mg once daily starting on Day 2. For smaller pediatric patients, dosing is weight-based. A healthcare provider determines the exact dose and duration.
Before and during treatment, clinicians may check liver-related blood tests and prothrombin time. This is not because every patient will have a problem, but because Veklury can be associated with liver enzyme changes, and COVID-19 itself can also affect the liver. Monitoring helps doctors separate routine bumps from warning signs that need action.
Veklury Side Effects
Like all prescription medicines, Veklury can cause side effects. Some are mild and manageable, while others require immediate medical attention. The most commonly reported side effect is nausea. Some people may also experience discomfort, bleeding, bruising, soreness, or swelling around the injection site.
Common or Less Serious Side Effects
- Nausea
- Injection-site pain, soreness, swelling, bleeding, or bruising
- Temporary changes in liver enzyme blood tests
- General discomfort during or after infusion
These effects do not automatically mean treatment must stop. However, patients should tell their care team about symptoms that are severe, persistent, or getting worse. The best side effect strategy is not heroic silence. Doctors are good, but they have not yet installed Bluetooth in everyone’s liver.
Serious Side Effects and Warning Signs
Serious reactions are less common but important. Veklury can cause allergic reactions, including infusion-related reactions and, rarely, anaphylaxis. These may happen during the infusion or after it is completed.
Patients should seek urgent medical help or alert the care team right away if they develop symptoms such as:
- Shortness of breath or wheezing
- Swelling of the lips, face, throat, or tongue
- Rash, hives, or severe itching
- Chest tightness, dizziness, or feeling faint
- Fast, slow, or irregular heartbeat
- Fever, sweating, shivering, or sudden nausea during infusion
Veklury may also increase liver enzymes. Signs that could suggest liver injury include yellowing of the skin or eyes, dark urine, pale stools, pain in the upper right side of the abdomen, unusual tiredness, loss of appetite, or ongoing nausea. These symptoms should be reported immediately.
Who Should Not Take Veklury?
People who have had a clinically significant allergic reaction to remdesivir or any ingredient in Veklury should not receive it. Patients should also tell their healthcare provider about liver disease, kidney disease, pregnancy, breastfeeding, immune system problems, and all medicines or supplements they take.
It is especially important to mention medicines containing chloroquine phosphate or hydroxychloroquine sulfate, because these may interfere with how remdesivir works. Even vitamins and herbal supplements deserve a quick mention. The supplement bottle may look innocent, but drug interactions do not care about cute labels.
Veklury Cost: How Much Does It Cost?
The cost of Veklury can be confusing because there is a difference between list price, hospital acquisition cost, insurance reimbursement, facility fees, infusion charges, and what a patient actually pays. In other words, the “price” is not one simple number wearing a name tag.
Gilead has publicly listed a U.S. commercial list price of $520 per vial for Veklury. Using that figure, an adult 5-day hospitalized course that uses 6 vials would equal about $3,120 for the drug alone before hospital, infusion, lab, or professional fees. A 3-day outpatient course for an adult or larger pediatric patient generally uses 4 vials, which would equal about $2,080 for the drug alone at that list price.
However, patients should not assume those numbers are their personal bill. Insurance coverage, Medicare or Medicaid rules, hospital billing practices, deductible status, outpatient infusion center charges, and financial assistance can dramatically change out-of-pocket cost. For outpatient use, Veklury has a permanent Medicare billing code, and reimbursement is handled differently depending on payer and setting.
Gilead’s Advancing Access program may help eligible patients understand insurance coverage and financial support options. Commercially insured patients may qualify for co-pay support, while uninsured patients may be directed toward patient assistance resources. Anyone prescribed Veklury should ask the hospital, infusion center, or prescribing office to estimate total costs, including administration and lab monitoring, not just the medication vial price.
Veklury vs. Paxlovid and Other COVID-19 Treatments
For many high-risk outpatients, clinicians often consider oral antiviral treatment first because pills are easier to take at home. Paxlovid, for example, is an oral antiviral combination taken for 5 days. But Paxlovid has important drug interaction considerations and may not be suitable for every patient.
Veklury can become especially relevant when a patient is at high risk but cannot take certain oral antivirals, has complex medication interactions, needs a supervised treatment setting, or is already hospitalized. The CDC has described a 3-day course of IV remdesivir as a preferred outpatient treatment option after ritonavir-boosted nirmatrelvir for eligible high-risk patients.
Molnupiravir is another oral antiviral option for some adults, but it is generally considered when preferred options are not appropriate or available. Monoclonal antibodies, once widely discussed, have had changing usefulness because viral variants can reduce their activity. This is why COVID-19 treatment advice can change over time: the virus keeps updating itself like the world’s least welcome software patch.
Does Veklury Work?
Clinical studies suggest that remdesivir can help certain patients when used appropriately and early enough. In a major study of hospitalized adults with COVID-19, patients treated with Veklury recovered faster than those who received placebo. In an outpatient study involving high-risk, nonhospitalized patients, a 3-day course of remdesivir reduced the risk of hospitalization or death compared with placebo.
That does not mean Veklury is magic. Its benefit depends on patient selection, timing, disease stage, immune status, and overall treatment plan. Antivirals tend to work best earlier in infection, when the virus is actively multiplying. Later in severe COVID-19, inflammation and organ stress may drive illness more than viral replication alone, so doctors may combine or prioritize other treatments.
Practical Questions to Ask Before Receiving Veklury
If Veklury is recommended, patients or caregivers may want to ask a few practical questions:
- Why is Veklury the right option for my situation?
- How many days of treatment do I need?
- Where will I receive the infusion?
- What symptoms should I report during or after infusion?
- Will I need liver blood tests or other monitoring?
- What will my estimated out-of-pocket cost be?
- Should I pause or avoid any medications while receiving treatment?
These questions are not annoying. They are exactly the kind of questions that make treatment safer, smoother, and less stressful. A good healthcare team would rather explain the plan clearly than have a patient silently wondering whether “infusion center” means a futuristic spa. It does not. Bring a book.
Real-World Experience: What Patients and Caregivers Often Notice
Experiences with Veklury can vary widely because the people receiving it are not all in the same situation. Some are hospitalized and very ill. Others are high-risk outpatients trying to avoid hospitalization. A young adult with immune suppression, a grandparent with heart disease, and a hospitalized patient needing oxygen may all receive the same medication, but their day-to-day experiences can feel completely different.
For outpatients, the biggest “experience” issue is often logistics. A 3-day IV course means arranging transportation, scheduling appointments, sitting for the infusion, and sometimes waiting afterward for observation. For someone who already feels feverish, tired, and achy, this can feel like a lot. Patients often appreciate knowing the plan in advance: where to park, whether they should wear a mask, how long the visit may take, and whether they can bring water, a phone charger, or a caregiver.
Another common experience is anxiety about side effects. Because Veklury is given through an IV, it can feel more intense than taking pills at home. Patients may worry when they hear about allergic reactions or liver enzyme monitoring. A calm explanation helps: monitoring does not mean doctors expect disaster; it means they are watching carefully. Many people tolerate the infusion without major issues, but the medical setting is designed to catch problems early.
Caregivers often focus on timing. COVID-19 treatment windows are short, and outpatient Veklury should be started early. Families may spend a hectic day calling the doctor, confirming test results, checking eligibility, and finding an infusion site. This can feel like trying to solve a puzzle while wrapped in a blanket and holding a thermometer. The best move is to call promptly after a positive test if the patient is high risk. Waiting “one more day to see” may reduce treatment options.
Hospitalized patients may experience Veklury as just one part of a larger care plan. They may receive oxygen, steroids, breathing treatments, fluids, or other medications. Because hospital days can blur together, patients or family members may not always know which treatment is responsible for improvement. It is reasonable to ask the care team what each medication is intended to do and how progress is being measured.
Cost experiences also differ. Some patients pay little because insurance covers most treatment. Others are surprised by separate charges for the medication, infusion administration, facility use, labs, or emergency department evaluation. Before outpatient treatment, asking for a benefits check can prevent financial whiplash. For hospitalized care, billing may be more complex, so patients should request an itemized bill and ask about financial assistance if needed.
The most useful mindset is practical rather than panicked. Veklury is not a casual medicine, but it is also not mysterious. It is a monitored antiviral treatment used for specific COVID-19 situations. Patients who understand why they are receiving it, what side effects to watch for, how the schedule works, and what costs may be involved tend to feel more prepared. And in healthcare, prepared is always better than surprisedunless the surprise is free parking, which almost never happens.
Conclusion
Veklury, also known as remdesivir, remains an important FDA-approved COVID-19 treatment for certain adults and children. It is made by Gilead Sciences and works as an antiviral medicine that interferes with viral replication. Because it is given by IV infusion, it requires a healthcare setting and medical monitoring.
Its main uses include treatment of hospitalized COVID-19 patients and treatment of high-risk nonhospitalized patients with mild-to-moderate COVID-19 when started early. The most common side effect is nausea, while serious concerns include allergic or infusion-related reactions and liver enzyme elevations. Cost depends heavily on insurance, treatment setting, dosing duration, facility charges, and financial assistance options.
For patients and caregivers, the key is simple: ask early, ask clearly, and do not guess. Veklury may be helpful for the right person at the right time, but the decision should always be made with a qualified healthcare professional who understands the patient’s medical history, COVID-19 risk, and treatment options.
